KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema

This publication has 23 references indexed in Scilit:

• HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
  Ophthalmology, 2020
• Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
  Eye, 2019
• Loss to Follow-up After Intravitreal Anti–Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema
  Ophthalmology Retina, 2019
• COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE
  Retina, 2018
• Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany
  Diabetes Therapy, 2018
• A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)
  Acta Ophthalmologica, 2018
• Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema
  Ophthalmology, 2017
• Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
  British Journal of Ophthalmology, 2015
• Intravitreal Aflibercept for Diabetic Macular Edema
  Ophthalmology, 2015
• Ranibizumab for Diabetic Macular Edema
  Ophthalmology, 2012